Evaluation of Recent Intranasal Drug Delivery Systems to the Central Nervous System
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Neurological diseases continue to increase in prevalence worldwide. Combined with the lack of modifiable risk factors or strongly efficacious therapies, these disorders pose a significant and growing burden on healthcare systems and societies. The development of neuroprotective or curative therapies is limited by a variety of factors, but none more than the highly selective blood-brain barrier. Intranasal administration can bypass this barrier completely and allow direct access to brain tissues, enabling a large number of potential new therapies ranging from bioactive peptides to stem cells. Current research indicates that merely administering simple solutions is inefficient and may limit therapeutic success. While many therapies can be delivered to some degree without carrier molecules or significant modification, a growing body of research has indicated several methods of improving the safety and efficacy of this administration route, such as nasal permeability enhancers, gelling agents, or nanocarrier formulations. This review shall discuss promising delivery systems and their role in expanding the clinical efficacy of this novel administration route. Optimization of intranasal administration will be crucial as novel therapies continue to be studied in clinical trials and approved to meet the growing demand for the treatment of patients with neurological diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oxytocin increases trust in humans
Kosfeld, M., Heinrichs, M., Zak, P. J., Fischbacher, U., & Fehr, E. (2005) · Nature · doi:10.1038/nature03701 · Cited by 3,690
The blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
Alzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642 · cited 1×
“Alzheimer’s Disease (AD) currently affects nearly 5 million Americans, incurring an annual estimated societal cost of >USD 100 billion [1,2].”
BackgroundSniffing neuropeptides: A transnasal approach to the human brain
Born, J., Lange, T., Kern, W., McGregor, G. P., Bickel, U., & Fehm, H. L. (2002) · Nature Neuroscience · doi:10.1038/nn0602-849 · Cited by 1,356
Intranasal delivery to the central nervous system: Mechanisms and experimental considerations
Dhuria, S. V., Hanson, L. R., & Frey, W. H. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21924 · Cited by 1,239
Intranasal delivery of biologics to the central nervous system
Lochhead, J. J., & Thorne, R. G. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.11.002 · Cited by 1,214
The Neuropeptide Oxytocin Regulates Parochial Altruism in Intergroup Conflict Among Humans
De Dreu, C. K. W., Greer, L. L., Handgraaf, M. J. J., Shalvi, S., Van Kleef, G. A., Baas, M., Ten Velden, F. S., Van Dijk, E., & Feith, S. W. W. (2010) · Science · doi:10.1126/science.1189047 · Cited by 1,148
Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus
Lai, S. K., O'Hanlon, D. E., Harrold, S., Man, S. T., Wang, Y.-Y., Cone, R., & Hanes, J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608611104 · Cited by 1,050
Transport of drugs from the nasal cavity to the central nervous system
Illum, L. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00087-7 · Cited by 907
Mechanism of intranasal drug delivery directly to the brain
Crowe, T. P., Greenlee, M. H. W., Kanthasamy, A. G., & Hsu, W. H. (2018) · Life Sciences · doi:10.1016/j.lfs.2017.12.025 · Cited by 721
Self-citationCharacteristics of Compounds that Cross the Blood-Brain Barrier
Banks, W. A. (2009) · BMC Neurology · doi:10.1186/1471-2377-9-s1-s3 · Cited by 710
Intranasal Drug Delivery: How, Why and What For?
Pires, A., Fortuna, A., Alves, G., & Falcão, A. (2009) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3nc79 · Cited by 641
Nasal drug delivery devices: characteristics and performance in a clinical perspective—a review
Djupesland, P. G. (2013) · Drug Delivery and Translational Research · doi:10.1007/s13346-012-0108-9 · Cited by 563
Physicochemical properties of mucus and their impact on transmucosal drug delivery
Leal, J., Smyth, H. D. C., & Ghosh, D. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.09.018 · Cited by 560
Gänger, S., & Schindowski, K. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10030116 · Cited by 447
Frey, A., Giannasca, K. T., Weltzin, R., Giannasca, P. J., Reggio, H., Lencer, W. I., & Neutra, M. R. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.3.1045 · Cited by 401
Craft, S., Raman, R., Chow, T. W., Rafii, M. S., Sun, C.-K., Rissman, R. A., Donohue, M. C., Brewer, J. B., Jenkins, C., Harless, K., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1840 · Cited by 389
CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery
Fransson, M., Piras, E., Burman, J., Nilsson, B., Essand, M., Lu, B., Harris, R. A., Magnusson, P. U., Brittebo, E., & Loskog, A. S. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-112 · Cited by 372
Quantitative analysis of the olfactory pathway for drug delivery to the brain
Thorne, R. G., Emory, C. R., Ala, T. A., & Frey, W. H. (1995) · Brain Research · doi:10.1016/0006-8993(95)00637-6 · Cited by 352
Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder
Sikich, L., Kolevzon, A., King, B. H., McDougle, C. J., Sanders, K. B., Kim, S.-J., Spanos, M., Chandrasekhar, T., Trelles, M. D. P., Rockhill, C. M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103583 · Cited by 298 · cited 2×
“to replicate the eff cts in humans [9].”
BackgroundDistribution of extracellular tracers in perivascular spaces of the rat brain
Ichimura, T., Fraser, P. A., & Cserr, H. F. (1991) · Brain Research · doi:10.1016/0006-8993(91)91275-6 · Cited by 215 · cited 1×
“Only the extracellular pathway in combination with the pulsatile movements of arteriole provides congruent transport times seen above [23,24].”
BackgroundYamasue, H., Okada, T., Munesue, T., Kuroda, M., Fujioka, T., Uno, Y., Matsumoto, K., Kuwabara, H., Mori, D., Okamoto, Y., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0097-2 · Cited by 185
Watanabe, T., Abe, O., Kuwabara, H., Yahata, N., Takano, Y., Iwashiro, N., Natsubori, T., Aoki, Y., Takao, H., Kawakubo, Y., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.3181 · Cited by 183
Djupesland, P. G., & Skretting, A. (2012) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2011.0924 · Cited by 170
Pardeshi, C. V., Rajput, P. V., Belgamwar, V. S., Tekade, A. R., & Surana, S. J. (2013) · Drug Delivery · doi:10.3109/10717544.2012.752421 · Cited by 141
Intranasal delivery of insulin via the olfactory nerve pathway
Renner, D. B., Svitak, A. L., Gallus, N. J., Ericson, M. E., Frey, W. H., & Hanson, L. R. (2012) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2012.01555.x · Cited by 116
Clevenger, S. S., Malhotra, D., Dang, J., Vanle, B., & IsHak, W. W. (2018) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125317737264 · Cited by 83
Cited by
Koo, J., Lim, C., & Oh, K. T. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s439181 · Cited by 174
“7,13,21,26 Small-molecule drugs of less than 200 nm are exceptionally acceptable due to the olfactory nerve axon’s size.”
BackgroundInfluentialTanaka, M., Araujo, A. C., Valenti, V. E., Guiguer, E. L., Catharin, V. C. S., Gualhardi, C. M., de Souza Bastos Mazuqueli Pereira, E., de Alvares Goulart, R., de Argolo Haber, R. S., de Carvalho, A. C. A., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052370 · Cited by 13
Mazura, A. D., & Pietrzik, C. U. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041268 · Cited by 9
“Although promising for some therapeutic agents, several clinical trials have produced disappointing data [15–18], indicating that further optimization is needed to increase the brain parenchyma penetration and distribution for a variety of therapeutics intended to use the nasal-brain delivery route [19,20].”
Background
Metadata
- Authors
- Crowe, T. P., & Hsu, W. H.
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2022-03-12
- Volume
- 14
- Issue
- 3
- Pages
- 629
- ISSN
- 1999-4923 (ISSN-L)
- OpenAlex
- W4220960596
- Cited by
- 183
- References
- 27
- FWCI
- 12.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.